Cardiovascular: Atherosclerosis Monocyte Adhesion - chemokines -oxidised LDL

The article investigates the role of different stimuli recognised to play an important part in atherosclerosis development (chemokines, cytokines, oxidised lipoproteins) on leukocyte adhesion to endothelial cells or purified adhesion molecules, under physiological flow conditions using Cellix’s VenaFlux platform and biochips.


Atherosclerosis is a chronic inflammatory disease that constitutes the primary cause of heart disease and stroke. It is a progressive condition characterised by the gradual accumulation of lipid material in the artery wall, [1].

Traditionally atherosclerosis was considered a simple lipid disorder, but now inflammation is recognised as an important factor in all stages of the disease, from its genesis to plaque rupture and associated thrombotic complications.

Fatty streaks, the hallmark of early atherosclerotic lesions, are composed of lipid-laden macrophages called foam cells, which originate from circulating blood monocytes.

Figure 1

Figure 1: Monocytes leave the blood stream to enter the sub-endothelial tissue (transmigration), after rolling, adhering and spreading on the endothelium. This multistep process involves the joint action of numerous chemokines and adhesion molecules. Of interest in atherosclerosis are MCP-1, a potent chemo-attractant for monocytes, and Fractalkine, which may act both as an adhesion molecule and a soluble chemokine. After transmigration, monocytes differentiate into macrophages, and the continuous uptake of oxidized LDL via scavenger receptors leads to the formation of foam cells, which will gradually build up the necrotic lipid core typical of atherosclerotic lesions.

Therefore, the recruitment of leukocytes, their adhesion to the arterial endothelium and subsequent migration into the intima are central events in the pathogenesis of atherosclerosis. This process is triggered by local production of chemokines: endothelial cells that are activated by inflammatory cytokines express adhesion molecules ex novo and synthesise chemokines and lipid chemo-attractants.

This process is triggered by local production of chemokines: endothelial cells that are activated by inflammatory cytokines express adhesion molecules ex novo and synthesize chemokines and lipid chemo-attractants. The responsiveness of a leukocyte to a chemokine is determined by its set of chemokine receptors. Chemokine binding activates a signal transduction cascade that leads to various effects, such as integrin activation and subsequent cell adhesion. Monocyte chemoattractant protein-1 (MCP-1/CCL2) has been indicated as a key player in the recruitment of monocytes from the blood stream into early atherosclerotic lesions and may be involved in other processes leading to thrombotic events.

MCP-1 has been shown to be present in macrophage-rich atherosclerotic plaques in humans. Furthermore, studies reported that MCP-1 receptor CCR2 expression is greatly enhanced in monocytes from hypercholesterolemic patients compared with normal controls. Inducers of MCP-1 expression include oxidized low-density lipoprotein and shear stress, two well documented atherogenic stimuli.

Increasing relevance in different steps of atherogenesis is being directed to Fractalkine (Fkn/CX3CL1), a member of the CX3C chemokine family. It consists of a transmembrane domain and an extended mucin-like stalk with a chemokine domain on top. Fkn is bound directly to the cell membrane, but a soluble form also exists through cleavage with an endogenous protease, and this form exhibits chemoattractant activity for T cells, monocytes and NK cells. The full- length cell-bound chemokine promotes strong adhesion of leukocytes to activated endothelial cells under physiological flow conditions. High levels of Fkn expression have been observed in human arteries with atherosclerotic lesions, adding evidence to its potential role in atherogenesis and cardiovascular pathophysiology.

Another important factor to be considered is oxidative stress, which is caused by an excess of reactive oxygen species (ROS) or diminished antioxidant ability against them. Oxidative stress increases with atherosclerosis risk factors such as obesity, diabetes, hypertension, hyperlipidaemia, smoking, and is considered to play a key role in the pathogenesis of atherosclerosis.

An initial event in atherosclerosis is LDL (low density lipoprotein) conversion into modified LDL or OxLDL (oxidized LDL) by factors including radicals, transition metals and lipoxygenases, in the sub-endothelial microenvironment. OxLDL has been shown to upregulate adhesion molecule expression on endothelial cells, increasing the recruitment of leukocytes at the site of the atherosclerotic lesion. It has also been reported that oxLDL, but not native LDL, induces MCP-1 production in vascular endothelial cells and smooth muscle cells.


Atherosclerosis, inflammation, MCP-1, fractalkine, oxLDL.


Proteins and antibodies:

  • rhVCAM-1

  • rhCX3CL1/Fractalkine

  • rhCCL2/MCP-1

  • rhTNFα

  • Monoclonal anti human integrin α4

  • Fluorescein-conjugated mouse anti-human VCAM-1, ICAM-1, E-selectin mAbs

  • Fluorescein-conjugated mouse IgG matched isotype control all from R&D

  • rhIFNγ from Sigma

  • oxLDL, oxidized with copper II sulphate (LDL from human plasma) from Kalen Biomedicals.


  • THP1-monocytic cell line, from ECACC

  • PBMC, isolated from healthy donors

  • HUVEC, isolated from patients giving written consent

Methods :

  • Vena8 Fluoro+ experiments: Vena8 Fluoro+ biochips were coated with 10 μg/ml of recombinant protein overnight, at 4°C. THP1 incubation with anti-integrin α4 mAb was for 15 min, 37°C. PBMC incubation with Fractakine (chemokine domain) or MCP-1 was for 30 min, 37°C. Flow assays were performed at 0.5 dyn/cm2 for 3 min.

  • Endothelial experiments under flow: HUVECs were seeded at 4 x 10^5 cell/cm2 and grown in static conditions for 48 h prior to flow experiments. Incubation with oxLDL (150 μg/ml) was for 16 h, 37°C. Stimulation with TNFα (50 μg/ml) or IFNγ (500 units/ml) was for 4 h, 37°C. Flow assays were performed at 0.5 dyne/cm2 for 5 min. Cell suspensions were always at a density of 2 x 10^6 cells/ml.

  • Image analysis: All images acquired during flow assays were analysed with Image Pro Premier analysis software.

  • Statistical analysis: All data are represented as mean ± SEM (n=3 or 4). Statistical analysis was performed with GraphPad Prism®5. ns: p>0.05; *: 0.01<p<0.05; **: 0.001<p<0.01; ***: p<0.001.

Results & Discussion

Atherosclerosis is a complex multifactorial inflammatory disease, with signalling cascades involving different adhesion molecules, chemokines, lipids etc. However, their interactions, their independent or complimentary and synergistic roles are still unclear. Cellix’s technology offers the possibility to perform a simple and physiologically relevant functional assay to study individual mechanisms or the combined effects of more stimuli, in relation to the initial steps in atherogenesis of cell recruitment and adhesion to the vascular wall.

Adhesion to VCAM-1, a major adhesion molecule expressed on inflamed endothelium, was completely inhibited when blocking the α4 integrin on THP1cells, see Figure 2. Interestingly, adhesion was not significantly reduced when looking at adhesion to endothelial cells, even with a concentration of anti-α4 mAb 100 times higher, see Figure 3. This suggests the idea that blocking adhesion to VCAM-1 only might not be enough to achieve a satisfactory decrease in leukocyte infiltration. Adhesion blockade to full- length Fractalkine was also studied using the soluble form of the chemokine to block CX3CR1 receptors on PBMCs, see Figure 4.

Figure 2

Figure 2: Adhesion blockade to VCAM-1. The inhibition profile of THP1 adhesion to VCAM-1 was measured using an anti-α4 mAb to block the α4β1 (VLA-4) receptor for VCAM-1. A non-linear regression was used to interpolate the data, with a hill slope of -1.076. Best fit IC50 value: 41.09 ng/ml.

Figure 3

Figure 3: THP1 adhesion to HUVECs. Endothelial cells were stimulated with inflammatory cytokines, either TNFα or IFNγ, and adhesion of THP1 was measured. THP1 were also treated with an anti-α4 mAb to block the integrin, but a non- significant inhibition of adhesion was shown. To assess the statistical difference, unpaired t-test (two-tailed p value) was performed, showing a non-significant difference between the samples treated or not with the anti-α4 mAb, for both TNFα and IFNγ stimulated endothelial cells.

Figure 4: Adhesion blockade to Fractalkine (full-length). The inhibition profile of PBMCs adhesion to Fkn was measured using the soluble form of Fkn (chemokine domain) to block the CX3CR1 receptor for Fkn. A non-linear regression was used to interpolate the data, with a hill slope of -0.4595. Best fit IC50 value: 5.543 ng/ml.

To verify if a synergistic effect existed between VCAM-1 and the chemo-tactic cytokine MCP-1 (CCL2), we studied the adhesion of PBMCs to purified human VCAM-1 using different concentrations of the chemo-kine. An increased affinity for the binding was manifested from a more consistent adhesion at the higher concentrations of MCP-1, see Figure 5.

Figure 5

Figure 5: Effect of MCP-1 on adhesion to VCAM-1. A significant increase in PBMC adhesion to VCAM-1 was shown upon stimulation with MCP-1, which therefore may be involved in integrin activation and enhanced affinity in the VCAM-1/VLA-4 axis. To assess the statistical difference, one- way ANOVA was performed, followed by Dunnett’s post-test to compare all columns to control (MCP-1 concentration=0).

Different considerations should be made for Fractalkine since MCP-1 was shown to cause no effect in relation to PBMC adhesion to the immobilized chemokine, see Figure 6. Consistently with studies on ApoE-/- mice, MCP-1 and Fkn, two important players in atherosclerosis initiation and development, were proved to have independent roles in promoting monocyte recruitment, [2]. It was shown that genetic deletions of MCP-1, Fkn, or their associated receptors, CCR2 and CX3CR1 respectively, considerably reduced lesion size in murine models, but the combined genetic deletion of both MCP-1 and Fkn, on an ApoE-/- background, resulted in a much greater reduction of atherosclerotic lesions. All these data suggest that, from a clinical perspective, a double blocking could lead to a significant improvement in atheroprotection.